Indications for: APONVIE
Prevention of postoperative nausea and vomiting (PONV).
Limitations of Use:
Not for treating established nausea and vomiting.
Give prior to induction of anesthesia. 32mg IV over 30secs. Flush with normal saline prior to and after administration.
Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms developed with previous use. Severe hepatic impairment. Pregnancy: avoid. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraception for 1 month after administration. Nursing mothers.
Substance P/NK1 receptor antagonist.
See Contraindications. Avoid concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods [eg, condoms, spermicides]).
Constipation, fatigue, headache.
Half-life: 12 hours. Mean plasma clearance: 4.4 L/h.
Generic Drug Availability: